Apple Tree Partners
Apple Tree Partners (ATP) is a life sciences venture capital firm that creates and builds biotechnology and therapeutics companies. Founded in 1999, ATP provides flexible capital, strategic insight, and operational resources to launch companies from pre‑IP concepts and spinouts through seed, clinical development, IPO and strategic transactions. The firm emphasizes research‑driven enterprises across life sciences sectors and supports portfolio teams with venture partners, entrepreneurs‑in‑residence, and in‑house operational capabilities.
Industries
Nr. of Employees
small (1-50)
Apple Tree Partners
230 Park Avenue, Suite 2800, New York, New York 10169
Portfolio
Launched to create antibodies targeting drug‑peptide:MHC neoantigens using the HapImmune™ platform; $30M Series A with $25M from ATP; co‑founded with NYU Langone Health inventors.
#Immuno‑oncology / antibody therapeutics
Develops RNA exon editing therapeutics; lead program targets ABCA4 retinopathies (Stargardt disease); described as an ATP company.
#RNA exon editing / genetic medicine (ophthalmology, neurological, neuromuscular)
Develops STAR platform TCR Vβ‑targeting therapeutics; lead program STAR0602/Invikafusp alfa in Phase 1/2 (START‑001); ATP company involved in formation and clinical advancement.
#Immuno‑oncology / T cell receptor (TCR) targeting biologics
Developing the Aliya™ Pulsed Electric Field (PEF) platform for soft tissue ablation and interventional oncology; formed by ATP.
#Medical device / interventional oncology and ablation (Pulsed Electric Field)
Developed AU‑007, a computationally designed IL‑2 antibody; ATP participated in Series A (reported $40M Series A from ATP).
#Immuno‑oncology / IL‑2‑based antibody therapeutics
Created by ATP to develop selective termination of protein synthesis (STOPS) small molecule therapeutics; launched with $75M from ATP.
#Small molecules / translation modulation (STOPS platform)
Launched to create antibodies targeting drug‑peptide:MHC neoantigens using the HapImmune™ platform; $30M Series A with $25M from ATP; co‑founded with NYU Langone Health inventors.
#Immuno‑oncology / antibody therapeutics
Develops RNA exon editing therapeutics; lead program targets ABCA4 retinopathies (Stargardt disease); described as an ATP company.
#RNA exon editing / genetic medicine (ophthalmology, neurological, neuromuscular)
Develops STAR platform TCR Vβ‑targeting therapeutics; lead program STAR0602/Invikafusp alfa in Phase 1/2 (START‑001); ATP company involved in formation and clinical advancement.
#Immuno‑oncology / T cell receptor (TCR) targeting biologics
Developing the Aliya™ Pulsed Electric Field (PEF) platform for soft tissue ablation and interventional oncology; formed by ATP.
#Medical device / interventional oncology and ablation (Pulsed Electric Field)
Developed AU‑007, a computationally designed IL‑2 antibody; ATP participated in Series A (reported $40M Series A from ATP).
#Immuno‑oncology / IL‑2‑based antibody therapeutics
Created by ATP to develop selective termination of protein synthesis (STOPS) small molecule therapeutics; launched with $75M from ATP.
#Small molecules / translation modulation (STOPS platform)